BELL POTTER

22 April 2024

Analyst John Hester 612 8224 2871

Authorisation Thomas Wakim 612 8224 2815

Recommendation

Buy (unchanged) Price \$0.071 Valuation \$0.15 (unchanged) Risk Speculative

GICS Sector

Pharmaceuticals & Biotechnology

Expected Return	
Capital growth	111%
Dividend yield	0.0%
Total expected return	111%
Company Data & Ratios	
Enterprise value	\$380.7m
Market cap	\$519.7m
Issued capital	7,319.8m
Free float	93%
Avg. daily val. (52wk)	\$3.4m
12 month price range	\$0.04 - \$0.15

Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.11	0.11	0.14
Absolute (%)	-33.64	-33.64	-47.86
Rel market (%)	-32.19	-34.69	-50.36

Absolute Price



SOURCE: IRESS

BELL POTTER SECURITIES LIMITED ABN 25 006 390 772 AFSL 243480

Imugene (IMU)

Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 8. Speculative securities may not be suitable for Retail Clients.

Core Assets Progressing Nicely

Kincell Partnership Release Key Resources

IMU recently announced a Development Partnership with Kincell in the United States whereby Kincell will take on the manufacturing responsibilities for Azer-cel. Kincell is a privately owned company specialising in the production of CAR-T therapies from its CGMP production facilities in Florida. Under the terms of the Development Partnership, Kincell will assume the lease of Imugene's manufacturing facility in North Carolina and some headcount.

The deal allows Imugene to re-focus on its core competency of research and development for new oncology drugs, rather than the operation of complex production facilities. Kincell is a well established contract manufacturing business in biologics and is ideally suited to the manufacturing operations which Imugene inherited with the Azer-cel acquisition of September 2023.

Inflexion Points Coming

IMU will receive up to US\$6m in cash upon certain milestones commencing with deal completion. The reduction in headcount is expected to amount to US\$32m in savings to Imugene over three years which is vital to extending the cash runway beyond the period when we expect interim data from the Phase 1b trial with Azer-cel. The deal includes a supply agreement whereby Kincell will manufacture Azer-cell to support ongoing clinical trials. This note also contains a snapshot of the latest progress on the company's three core asset programs. Each of these is moving towards pivotal points in development which should manifest in meaningful clinical data within the next 6 to 12 months.

Investment View: Maintain Buy (Spec) Valuation \$0.15

The company remains well funded with cash at 31 December of \$139m. The Development Partnership with Kincell will free up crucial management time and resources to concentrate on the clinical programs each of which are moving toward value inflexion points. Retain Buy (Spec) recommendation and valuation \$0.15. Earnings revisions have been driven by the recent transaction to acquire Azer-cel.

Earnings	Forecast

June Year End	FY23	FY24e	FY25e	FY26e
Revenues \$m	10.5	16.0	21.6	44.3
EBIT \$m	-41.0	-115.9	-63.0	-40.3
NPAT (underlying) \$m	-39.1	-95.9	-61.0	-39.8
NPAT (reported) \$m	-39.1	-111.9	-61.0	-39.8
EPS underlying (cps)	-0.6	-1.3	-0.9	-0.6
EPS growth %	nm	nm	nm	nm
PER (x)	nm	nm	nm	nm
FCF yield (%)	nm	nm	nm	nm
EV/EBITDA (x)	nm	nm	nm	nm
Dividend (cps)	-	-	-	-
Franking	0%	0%	0%	0%
Yield %	0%	0%	0%	0%
ROE %	-21%	-66%	-61%	-66%

DISCLAIMER: THIS REPORT MUST BE READ WITH THE DISCLAIMER ON PAGE 8 THAT FORMS PART OF IT. DISCLOSURE: BELL POTTER SECURITIES ACTED AS LEAD MANAGER OF THE COMPANY'S SEPTEMBER 2023 CAPITAL RAISE FOR \$53M AND RECEIVED FEES FOR THAT SERVICE.

Core Assets Progressing Nicely

AZER-CEL

The phase 1b study is a multicentre, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate safety and tolerability. The study will determine the appropriate dose to optimize safety and efficacy, and evaluate clinical activity of Azer cel in subjects with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkins lymphoma (NHL).


The company is targeting 10 to 15 patients that have failed on autologous CAR-T therapy. First patient was enrolled in November 2023. Assuming 1 to 2 enrolments per month we expect enrolment should be approaching completion by mid CY2024.

Earlier studies in the same refractory population had shown Azer-cel achieved a complete response of 61% (n=18). Most patients had a duration of response extending > 6 months.

Following completion of the current phase 1b the company intends to move to a phase 2 study which may also support an application for accelerated approval based on unmet need.

CF-33

CF-33 (aka VAXINIA) is the company's proprietary oncolytic virus. The phase 1 MAST study is a multi-arm dose escalation clinical trial that is now approaching completion following 2 years of painstaking dose escalation.



Further dose escalation to continue as long as no safety issues are observed

SOURCE: COMPANY DATA

The VAXINIA monotherapy cohorts are all but complete and now at the dose where we would expect to see a therapeutic impact.

The fifth and final cohort in the monotherapy section of the trial has now been cleared by the cohort review committee. The combination study with pembrolizumab is now also nearing completion.

IMU has commenced enrolment of an expansion study in 10 patients with bile duct cancers following encouraging early results in this indication as summarised here.

Patient A – three previous lines of therapy, received a mid-dose of CF33 via intratumoural injection and achieved a complete response with duration of response out to at least 430 days; and

Patient B – also failed on multiple lines of therapy, received a mid-dose of CF-33 via IV and achieved stable disease.

The three key points are:

- Both patients had failed on multiple therapies and should be considered as very difficult to treat and unlikely to respond to further lines of conventional therapy;
- Patient B was dosed via IV yet sufficient drug found its way to tumour in order to have a therapeutic effect; and
- The monotherapy response is encouraging. Potential buyers will be encouraged. Future combinations with immuno-oncology drugs are more likely to create a synergistic effect where there are two distinct modes of action.

WHAT WOULD GET PHARMA BUYERS EXCITED

Later this year we expect further updates on efficacy signals from patients dosed at the maximum dose. Some of the points to look for include:

- Analysis of the tumour micro environment demonstrating infiltration of virus, virus replication and increased level of immune check point molecules including PD-L1.
- If the virus is able to replicate within the cancer cells, we would also expect to see an abscopal effect in nearby cancers and this would be an exceptional result – particularly in patients dosed via IV.
- Duration of response the overall response rate is important, however, duration
 of response is equally relevant. DoR is a proxy for progression free survival and
 ultimately overall survival. Among the patients who do respond, the percentage of
 patients with a DoR >6 months is a relevant benchmark.
- Synergistic effect of the combination study with pembrolizumab in cancer types where pembrolizumab has had minimal effect as a monotherapy.

We expect this detailed analysis to emerge from 2H24 onwards.

ONCARLYTICS

onCARlytics is a CD19-expressing oncolytic virus (CF33-CD19) that enters tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeted therapies. The OASIS trial commenced patient enrolment in February 2024 and is expected to recruit up to 52 patients with advanced or metastatic tumours.

This ambitious study is a world first and is likely to generate significant interest as the data emerges.

The intratumoural monotherapy section of the trial (with the CF33-CD19 virus alone) is complete and the study is now commencing the combination with the CD-19 targeting therapy Blincyto. The study will be conducted across multiple solid tumour types as investigators assess toxicity and look for early signs of responses.

Data is likely to take several months to emerge.

	2024			2025			2026	
New	Old	% change	New	Old	% change	New	Old	% change
16.0	14.0	14%	21.6	21.6	0%	44.3	44.3	0%
-115.9	-42.2	-175%	-63.0	-35.7	-76%	-40.3	-32.0	-26%
-111.9	-40.2	-178%	-61.0	-33.7	-81%	-39.8	-31.5	-26%
-1.3	-0.6	-123%	-0.9	-0.5	-70%	-0.6	-0.4	-39%
	16.0 -115.9 -111.9 -1.3	New Old 16.0 14.0 -115.9 -42.2 -111.9 -40.2	New Old % change 16.0 14.0 14% -115.9 -42.2 -175% -111.9 -40.2 -178% -1.3 -0.6 -123%	New Old % change New 16.0 14.0 14% 21.6 -115.9 -42.2 -175% -63.0 -111.9 -40.2 -178% -61.0 -1.3 -0.6 -123% -0.9	New Old % change New Old 16.0 14.0 14% 21.6 21.6 -115.9 -42.2 -175% -63.0 -35.7 -111.9 -40.2 -178% -61.0 -33.7 -1.3 -0.6 -123% -0.9 -0.5	New Old % change New Old % change 16.0 14.0 14% 21.6 21.6 0% -115.9 -42.2 -175% -63.0 -35.7 -76% -111.9 -40.2 -178% -61.0 -33.7 -81% -1.3 -0.6 -123% -0.9 -0.5 -70%	New Old % change New Old % change New 16.0 14.0 14% 21.6 21.6 0% 44.3 -115.9 -42.2 -175% -63.0 -35.7 -76% -40.3 -111.9 -40.2 -178% -61.0 -33.7 -81% -39.8 -1.3 -0.6 -123% -0.9 -0.5 -70% -0.6	New Old % change New Old % change New Old 16.0 14.0 14% 21.6 21.6 0% 44.3 44.3 -115.9 -42.2 -175% -63.0 -35.7 -76% -40.3 -32.0 -111.9 -40.2 -178% -61.0 -33.7 -81% -39.8 -31.5 -1.3 -0.6 -123% -0.9 -0.5 -70% -0.6 -0.4

SOURCE: BELL POTTER SECURITIES ESTIMATES

The main driver of earnings changes includes the amalgamation of costs associated with the asset purchase from Precision Bioscience. We expect the loss will reduce in FY25 following the divestment of staff costs and as other R&D programs conclude. We maintain our Buy (Speculative) rating and valuation of \$0.15.

Imugene

Imugene is a drug developer specialising in the development of new agents for various cancer indications. The company has a history of in-licensing early stage assets, typically pre-clinical or with phase 1 data, and progressing their development. Consequently, the risk of failure is probably high, however the future financial benefit from development of a new chemical entity for the treatment of disease are immense.

The key risk include but are not limited to the follow items:

Imugene's ability to achieve profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for its products (including HER-Vex, PD1-Vaxx, CF33, Azer-cel and onCARlytics) and successfully commercialise or out license those products. There is no guarantee that Imugene's products will be commercially successful.

Imugene does not currently generate revenue from product sales or license income and no revenues are anticipated in the short to medium term.

Clinical trial risk

IMU may be unable to secure necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct future clinical trials. There is also no assurance that products developed using the Company's technology will prove to be safe and efficacious in clinical trials, or that the regulatory approval to manufacture and market its products will be received. Clinical trials might also potentially expose the Company to product liability claims in the event its products in development have unexpected effects on clinical subjects.

Products, including HER-Vaxx, PD1-Vaxx, CF33 and onCARlytics, developed using the Company's technology must undergo a comprehensive and highly regulated development and review process before receiving approval for marketing. In addition there are numerous, well funded competitors who may achieve breakthroughs in cancer treatment ahead of IMU which may diminish the value of IMU's assets.

The Company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and there is a risk that, once developed and ready for sale, commercial sales to fund sufficient revenues for continued operations and growth, may not be achieved.

Arrangements with third-party collaborators

Imugene may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. These collaborators may be asked to assist with funding or performing clinical trials, manufacturing, regulatory approvals or product marketing. There is no assurance that Imugene will attract and retain appropriate strategic partners or that any such collaborators will perform and meet commercialisation goals. If Imugene is unable to find a partner, it would be required to develop and commercialise HER-Vaxx, PD1-Vaxx or CF33 (and other potential products) at its own expense. This may place significant demands on the Company's internal resources and potentially delay the commercialisation of HER-Vaxx, PD1-Vaxx, CF33 (and other products).

Requirement to raise additional funds

The Company may be required to raise additional equity or debt capital in the future. There is no assurance that it will be able to raise that capital when it is required or, even if available, the terms may be unsatisfactory. If the Company is unsuccessful in obtaining funds when they are required, the Company may need to delay or scale down its operations.

Intellectual property

The Company's ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the Company may incur substantial costs in asserting or defending its intellectual property rights.

Imugene as at 22 April 2024

Recommendation	Buy, Speculative
Price	\$0.071
Valuation	\$0.15

Market Cap \$m

\$ 519.7

Table 1 - Financial summary

	FY22	FY23	FY24e	FY25e	FY26e
Year Ending June	1122	1120	11240	11200	11200
U	10.0	10.5	10.0		
R&D incentive	13.0	10.5	16.0	14.0	14.0
Deal revenue (milestones/royalty income)	-	-	-	7.6	30.3
Total Revenue	13.0	10.5	16.0	21.6	44.3
Other income	-0.2	-0.2	0.2	0.0	0.0
R&D Expense	-36.6	-30.9	-50.0	-50.0	-50.0
General and admin	-14.1	-20.4	-65.0	-34.6	-34.6
Add back D&A	0.2	2.2	5.0	5.0	5.0
Net expenses	-50.7	-49.3	-109.8	-79.6	-79.6
EBITDA	-37.7	-41.0	-93.8	-58.0	-35.3
Revaluation p'vn movement	0.0	0.0	-17.1	0.0	0.0
D&A	-0.2	-2.2	-5.0	-5.0	-5.0
EBIT	-37.9	-41.0	-115.9	-63.0	-40.3
Interest income	0.1	1.9	4.0	2.0	0.5
Pre tax profit	(37.9)	(39.1)	(111.9)	(61.0)	(39.8)
Tax expense	-	-	-	-	-
NPAT- reported	(37.9)	(39.1)	(111.9)	(61.0)	(39.8)
Add back abnrmal	0.0	0.0	16.0	0.0	0.0
Reported NPAT	(37.9)	(39.1)	(95.9)	(61.0)	(39.8)

Cashflow (A\$m)	FY22	FY23	FY24e	FY25e	FY26e
EBITDA	-37.7	-41.0	-93.8	-58.0	-35.3
Working capital movement	6.9	10.5	4.6	2.3	0.3
Net interest	0.2	1.7	4.0	2.0	0.5
Operating cash flow	-30.6	-28.8	-85.2	-53.6	-34.4
Proceeds from asset sales	0.0	0.0	0.0	0.0	0.0
Free cash flow	-30.6	-28.8	-85.2	-53.6	-34.4
Payment for PP&E	-0.3	0.0	-7.7	0.0	0.0
Acquistion of intangibles	-0.1	0.0	-8.7	0.0	0.0
Payment for other assets	0.0	0.0	-4.9	0.0	0.0
Payment - contingent liabilities	0.0	0.0	-2.0	0.0	0.0
Proceeds from issuance	102.7	83.1	50.9	0.0	0.0
Other	-1.4	-0.1	-0.3	0.0	0.0
Change in cash held	70.3	54.2	-57.9	-53.6	-34.4
Cash at beginning of period	29.5	99.9	153.2	95.2	42.1
FX adjustment	0.1	-0.9	0.0	0.0	0.0
Cash at year end	99.9	153.2	95.2	42.1	7.7

Balance Sheet (A\$m)	FY22	FY23	FY24e	FY25e	FY26e
Cash	99.9	153.2	95.2	42.1	7.7
Receivables	12.8	10.8	15.0	15.0	15.0
Other current assets	1.1	0.4	8.0	8.0	8.0
Property, Plant and Equipment	0.9	0.7	23.0	23.0	23.0
Intangibles	32.7	30.5	35.2	30.2	25.2
Other non current assets	0.3	0.2	2.9	2.9	2.9
Total assets	147.6	195.8	179.3	121.2	81.7
Trade payables	5.3	3.5	5.0	7.0	7.0
Provisions		0.5	3.9	4.1	4.3
Contract liabilities		1.9	16.3	-	-
Other current		0.2	2.3	2.4	2.5
Current Liabilities	5.3	6.1	27.5	13.5	13.8
Contract liability (Precision Bioscience)		1.0	3.1	3.6	3.6
Other provisions - non current	3.6	0.4	4.4	4.4	4.4
Non current liabilities	3.6	1.4	7.5	8.0	8.0
Total Liabilities	8.9	7.5	35.0	21.5	21.8
Net Assets	138.7	188.3	144.3	99.7	59.9
Share capital	230.8	314.4	365.3	400.1	400.1
Other equity	4.7	4.6	4.7	4.8	4.8
Retained earnings	(103.6)	(142.7)	(254.6)	(315.6)	(355.4)
Reserves	6.8	12.0	29.0	10.4	10.4
Shareholders Equity	138.7	188.3	144.3	99.7	59.9

SOURCE: BELL POTTER SECURITIES ESTIMATES

	•					
Share price \$	\$	0.071				
Enterprise value \$m	\$	380.7				
Valuation Ratios (A\$m)		FY22	FY23	FY24e	FY25e	FY26e
Reported EPS (cps)		-0.7	-0.6	-1.6	-0.9	-0.6
Normalised EPS (cps)		-0.7	-0.6	-1.3	-0.9	-0.6
EPS grow th (%)		nm	nm	nm	nm	nm
PE(x)		nm	nm	nm	nm	nm
EV/EBIT (x)		nm	nm	nm	nm	nm
P/NTA (x)		3.3	2.9	4.7	7.3	14.7
Book Value Per Share (cps)		2.8	2.9	2.0	1.4	0.8
Price/Book (x)		2.5	2.4	3.5	5.1	8.5
DPS (cps)		-	-	-	-	-
Payout ratio %		0%	0%	0%	0%	0%
Dividend Yield %		0.0%	0.0%	0.0%	0.0%	0.0%
Franking %		0%	0%	0%	0%	0%
FCF yield %		nm	nm	nm	nm	nm
Net debt/Equity		0%	0%	0%	0%	0%
Net debt/Assets		0%	0%	0%	0%	0%
Gearing		net cash				
Net debt/EBITDA (x)		n/a	n/a	n/a	n/a	n/a
Interest cover (x)		n/a	n/a	n/a	n/a	n/a

Interim analysis	1H23	2H23	1H24	2H24e
Revenues	4.8	5.7	8.1	7.9
Net expenses	-21.6	-27.7	-60.1	-49.7
EBITDA	-16.8	-24.2	-52.0	-41.8
Provision adjustment	0.0	0.0	-17.1	0.0
D&A	-1.1	0.0	-1.9	-3.1
EBIT	-17.9	-23.1	-71.0	-44.9

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

Staff Member	Title/Sector	Phone	@bellpotter.com.au
Chris Savage	Head of Research/Industrials	612 8224 2835	csavage
Analysts			
John Hester	Healthcare	612 8224 2871	jhester
Martyn Jacobs	Healthcare	613 9235 1683	mjacobs
Thomas Wakim	Healthcare	612 8224 2815	twakim
Michael Ardrey	Industrials	613 9256 8782	mardrey
Marcus Barnard	Industrials	618 9326 7673	mbarnard
Sam Brandwood	Industrials	612 8224 2850	sbrandwood
Joseph House	Industrials	613 9325 1624	jhouse
Daniel Laing	Industrials	612 8224 2886	dlaing
Hayden Nicholson	Industrials	613 92351757	hnicholson
Chami Ratnapala	Industrials	612 8224 2845	cratnapala
Jonathan Snape	Industrials	613 9235 1601	jsnape
Connor Eldridge	Real Estate	612 8224 2893	celdridge
Andy MacFarlane	Real Estate	612 8224 2843	amacfarlane
Regan Burrows	Resources	618 9236 7677	rburrows
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9325 1856	showe
Brad Watson	Resources	618 9326 7672	bwatson
James Williamson	Resources	613 9235 1692	jwilliamson
Associates			
Leo Armati	Associate Analyst	612 8224 2846	larmati
Baxter Kirk	Associate Analyst	613 9235 1625	bkirk
Kion Sapountzis	Associate Analyst	613 9235 1824	ksapountzis
Ritesh Varma	Associate Analyst	613 9235 1658	rvarma

Disclosures **Research Coverage & Policies**

For Bell Potter Securities' Research Coverage Decision Making Process and Research Independence Policy please refer to our company website: https://bellpotter.com.au/research-independence-policy/.

Authoring Research Analyst's Certification

The Authoring Research Analyst is responsible for the content of this Research Report, and, certifies that with respect to each security that the Analyst covered in this Report (1) all the views expressed accurately reflect the Analyst's personal views about those securities and were prepared in an independent manner and (2) no part of the Analyst's compensation was, is or will be, directly or indirectly, related to specific recommendations or views expressed by that Research Analyst in the Research Report.

Research Analyst's Compensation

Research Analyst's compensation is determined by Bell Potter Securities Research Management and Bell Potter Securities' Senior Management and is based upon activities and services intended to benefit the investor clients of Bell Potter Securities Ltd. Compensation is not linked to specific transactions or recommendations. Like all Company employees Research Analysts receive compensation that is impacted by overall Company profitability.

Prices

The Price appearing in the Recommendation panel on page 1 of the Research Report is the Closing Price on the Date of the Research Report (appearing in the top right hand corner of page 1 of the Research Report), unless a before midday (am) time appears below the Date of the Research Report in which case the Price appearing in the Recommendation panel will be the Closing Price on the business day prior to the Date of the Research Report.

Availability

The completion and first dissemination of a Recommendation made within a Research Report are shortly after the close of the Market on the Date of the Research Report, unless a before midday (am) time appears below the Date of the Research Report in which case the Research Report will be completed and first disseminated shortly after that am time.

Disclosure of Interest

Disclosure: Bell Potter Securities acted as Lead manager of the company's September 2023 capital raise for \$53m and received fees for that service.

Dissemination

Bell Potter generally disseminates its Research to the Company's Institutional and Private Clients via both proprietary and nonproprietary electronic distribution platforms. Certain Research may be disseminated only via the Company's proprietary distribution platforms; however such Research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the Author's previously published Research. Certain Research is made available only to institutional investors to satisfy regulatory requirements. Individual Bell Potter Research Analysts may also opt to circulate published Research to one or more Clients by email; such email distribution is discretionary and is done only after the Research has been disseminated.

The level and types of service provided by Bell Potter Research Analysts to Clients may vary depending on various factors such as the Client's individual preferences as to frequency and manner of receiving communications from Analysts, the Client's risk profile and investment focus and perspective (e.g. market-wide, sector specific long term and short term etc.) the size and scope of the overall Client relationship with the Company and legal and regulatory constraints.

Disclaimers

This Research Report is a private communication to Clients and is not intended for public circulation or for the use of any third party, without the prior written approval of Bell Potter Securities Limited.

The Research Report is for informational purposes only and is not intended as an offer or solicitation for the purpose of sale of a security. Any decision to purchase securities mentioned in the Report must take into account existing public information on such security or any registered prospectus.

This is general investment advice only and does not constitute personal advice to any person. Because this Research Report has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited Broker (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this Research Report.

While this Research Report is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in this document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee expressly or impliedly, that the information contained in this Research Report is complete or accurate.

Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views, opinions or recommendations contained in this Research Report or for correcting any error or omission which may have become apparent after the Research Report has been issued.

Bell Potter Securities Research Department has received assistance from the Company referred to in this Research Report including but not limited to discussions with management of the Company. Bell Potter Securities Policy prohibits Research Analysts sending draft Recommendations, Valuations and Price Targets to subject companies. However, it should be presumed that the Author of the Research Report has had discussions with the subject Company to ensure factual accuracy prior to publication.

All opinions, projections and estimates constitute the judgement of the Author as of the Date of the Research Report and these, plus any other information contained in the Research Report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice.

Notwithstanding other departments within Bell Potter Securities Limited advising the subject Company, information obtained in such role is not used in the preparation of the Research Report.

Although Bell Potter Research does not set a predetermined frequency for publication, if the Research Report is a fundamental equity research report it is the intention of Bell Potter Research to provide research coverage of the covered issuers, including in response to news affecting the issuer. For non-fundamental Research Reports, Bell Potter Research may not provide regular updates to the views, recommendations and facts included in the reports.

Notwithstanding that Bell Potter maintains coverage on, makes recommendations concerning or discusses issuers, Bell Potter Research may be periodically restricted from referencing certain Issuers due to legal or policy reasons. Where the component of a published trade idea is subject to a restriction, the trade idea will be removed from any list of open trade ideas included in the Research Report. Upon lifting of the restriction, the trade idea will either be re-instated in the open trade ideas list if the Analyst continues to support it or it will be officially closed.

Bell Potter Research may provide different research products and services to different classes of clients (for example based upon longterm or short term investment horizons) that may lead to differing conclusions or recommendations that could impact the price of a security contrary to the recommendations in the alternative Research Report, provided each is consistent with the rating system for each respective Research Report.

Except in so far as liability under any statute cannot be excluded, Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in the document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of the document or any other person.

In the USA and the UK this Research Report is only for institutional investors. It is not for release, publication or distribution in whole or in part in the two specified countries. In Hong Kong this Research Report is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. In the United States this Research Report is being distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this Research Report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC.

Biotechnology Risk Warning

The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek U.S. FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock.

Bell Potter Securities Limited ABN 25 006 390 772 Level 29, 101 Collins Street Melbourne, Victoria, 3000 Telephone +61 3 9256 8700 www.bellpotter.com.au Bell Potter Securities (HK) Limited Room 1601, 16/F Prosperity Tower, 39 Queens Road Central, Hong Kong, 0000 Telephone +852 3750 8400 Bell Potter Securities (US) LLC Floor 39 444 Madison Avenue, New York NY 10022, U.S.A Telephone +1 917 819 1410

Bell Potter Securities (UK) Limited 16 Berkeley Street London, England W118DZ, United Kingdom

W1J 8DZ, United Kingdom Telephone +44 7734 2929